See more : Realco S.A. (REAL.BR) Income Statement Analysis – Financial Results
Complete financial analysis of Fennec Pharmaceuticals Inc. (FENC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fennec Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Caffyns plc (CFYN.L) Income Statement Analysis – Financial Results
- Advantage Solutions Inc. (ADV) Income Statement Analysis – Financial Results
- Satori Resources Inc. (BUD.V) Income Statement Analysis – Financial Results
- Wiluna Mining Corporation Limited (WMC.AX) Income Statement Analysis – Financial Results
- Springview Holdings Ltd Class A Ordinary Shares (SPHL) Income Statement Analysis – Financial Results
Fennec Pharmaceuticals Inc. (FENC)
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.25M | 1.54M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.68 |
| Cost of Revenue | 1.26M | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -55.23K | 0.00 |
| Gross Profit | 19.99M | 1.45M | 0.00 | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.23K | 0.68 |
| Gross Profit Ratio | 94.08% | 94.40% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8,359,700.00% | 100.00% |
| Research & Development | 56.00K | 3.53M | 4.98M | 5.11M | 5.61M | 5.01M | 1.94M | 472.00K | 256.00K | 357.00K | 597.00K | 2.08M | 1.49M | 708.00K | 2.11M | 10.37M | 10.91M | 14.00M | 12.44M | 3.59M | 3.55M | 3.13M | 1.91M | 939.36K |
| General & Administrative | 20.59M | 17.72M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.12M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.71M | 20.51M | 12.24M | 12.95M | 7.40M | 5.40M | 5.02M | 2.40M | 1.63M | 2.52M | 1.33M | 1.55M | 1.94M | 3.90M | 1.21M | 3.52M | 3.28M | 2.88M | 3.18M | 3.49M | 1.78M | 907.40K | 738.72K | 614.25K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.00K | -17.00K | 6.00K | -8.00K | -14.00K | 0.00 | 0.00 | -3.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.18M | 2.72M | 2.34M | 1.42M | 0.00 | 55.23K | 52.01K |
| Operating Expenses | 32.76M | 24.04M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.70M | 1.61M |
| Cost & Expenses | 34.06M | 24.12M | 17.22M | 18.06M | 13.01M | 10.41M | 6.95M | 2.87M | 1.89M | 2.88M | 1.93M | 3.62M | 3.44M | 4.60M | 2.83M | 13.89M | 14.19M | 19.06M | 18.35M | 9.42M | 6.74M | 4.04M | 2.65M | 1.61M |
| Interest Income | 441.00K | 195.00K | 54.00K | 87.00K | 322.32K | 0.00 | 0.00 | 0.00 | 3.00K | 2.00K | 2.00K | 25.00K | 43.00K | 32.00K | 47.00K | 286.00K | 833.00K | 0.00 | 361.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.39M | 978.00K | 126.00K | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00K | 11.00K | -444.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 287.00K | 149.00K | 17.22M | 402.00K | 13.01M | 10.41M | 6.95M | 2.87M | -1.23M | -699.00K | -1.00K | 20.00K | 43.00K | 3.25M | 615.00K | 164.00K | 192.00K | 2.43M | 3.06M | 2.52M | 1.61M | 123.76K | 55.23K | 52.01K |
| EBITDA | -12.36M | -22.59M | -123.00K | -17.89M | 234.00K | 521.00K | -95.00K | 82.00K | -1.89M | -2.88M | 1.79M | -5.18M | 4.55M | -4.60M | -2.60M | -13.89M | -14.19M | -17.91M | -19.27M | -12.56M | -5.22M | -4.24M | -2.79M | -2.59M |
| EBITDA Ratio | -58.18% | -1,468.60% | 0.00% | -10,579.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -421,928,118.14% | -231,162,432.56% |
| Operating Income | -12.77M | -22.59M | -17.22M | -17.89M | -13.01M | -10.41M | -6.95M | -2.87M | -1.89M | -2.88M | -1.93M | -3.62M | -3.44M | -4.60M | -3.22M | -13.89M | -14.19M | -19.06M | -18.35M | -9.42M | -6.74M | -4.04M | -2.65M | -1.61M |
| Operating Income Ratio | -60.09% | -1,471.60% | 0.00% | -10,520.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -400,900,112.25% | -237,629,943.17% |
| Total Other Income/Expenses | -3.27M | -1.13M | -123.00K | -224.00K | 234.00K | 521.00K | -95.00K | 82.00K | 1.28M | 701.00K | 3.78M | -1.54M | 8.12M | -3.51M | 204.00K | 0.00 | 905.96K | -1.54M | -3.99M | -227.00K | 79.44K | 321.36K | 194.17K | 8.31K |
| Income Before Tax | -16.05M | -23.71M | -17.35M | -18.11M | -12.78M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -20.64M | -21.54M | -9.59M | -6.67M | -3.72M | -2.45M | -1.60M |
| Income Before Tax Ratio | -75.50% | -1,544.89% | 0.00% | -10,652.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| Income Tax Expense | 0.00 | 1.13M | 110.00K | -187.00K | -315.00K | -348.00K | -47.00K | -8.00K | -3.00K | -2.00K | -2.00K | -25.00K | -43.00K | 7.82M | 3.01M | 13.60M | 13.36M | -1.54M | -2.29M | -854.68K | -518.20K | 3.72M | 2.45M | 1.60M |
| Net Income | -16.05M | -24.84M | -17.46M | -17.92M | -12.46M | -9.89M | -7.05M | -2.79M | -659.00K | -2.18M | 1.85M | -5.16M | 4.69M | -7.82M | -3.01M | -13.60M | -13.36M | -19.10M | -19.25M | -8.74M | -6.15M | -3.72M | -2.45M | -1.60M |
| Net Income Ratio | -75.50% | -1,618.18% | 0.00% | -10,542.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -371,512,604.02% | -236,400,367.04% |
| EPS | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.19 | -0.63 | 0.59 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -20.12 | -2.98 |
| EPS Diluted | -0.60 | -0.95 | -0.67 | -0.76 | -0.63 | -0.52 | -0.47 | -0.22 | -0.06 | -0.22 | 0.17 | -0.62 | 0.58 | -1.11 | -0.98 | -4.43 | -4.78 | -16.72 | -20.45 | -15.04 | -19.85 | -19.32 | -4.04 | -2.98 |
| Weighted Avg Shares Out | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 18.94M | 14.99M | 12.68M | 10.83M | 9.87M | 9.72M | 8.20M | 7.99M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 122.02K | 536.64K |
| Weighted Avg Shares Out (Dil) | 26.57M | 26.28M | 26.01M | 23.70M | 19.90M | 19.02M | 15.01M | 12.77M | 10.83M | 9.87M | 10.57M | 8.39M | 8.02M | 7.08M | 3.07M | 3.07M | 2.79M | 1.14M | 941.26K | 580.75K | 309.64K | 192.51K | 607.09K | 536.64K |
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's...
Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram...
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.07 per share a year ago.
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~...
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of...
Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host...
Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig Hallum Naureen Quibria -...
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports